Compare ASE Technology Holding Co Ltd (ASX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs Sana Biotechnology Inc — how do they compare? ASE Technology Holding Co Ltd trades at $41.6 (market cap $92.88B), while Sana Biotechnology Inc trades at $3.69 (market cap $1.07B). The key difference: ASE Technology Holding Co Ltd is far larger — about 86.8× Sana Biotechnology Inc's market cap, and ASE Technology Holding Co Ltd pays a 0.98% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ASX | SANA | |
|---|---|---|
Market Cap | $92.88B | $1.07B |
Sector | Technology | Health |
52-Week High | $45.12 | $5.92 |
52-Week Low | $9.50 | $2.68 |
Enterprise Value | $97.32B | $1.04B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.
Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
